|
1
|
Jones GW, Mettlin C, Murphy GP, et al:
Patterns of care for carcinoma of the prostate gland: Results of a
national survey of 1984 and 1990. J Am Coll Surg. 180:545–554.
1995.PubMed/NCBI
|
|
2
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohori M, Wheeler TM, Kattan MW, Goto Y and
Scardino PT: Prognostic significance of positive surgical margins
in radical prostatectomy specimens. J Urol. 154:1818–1824. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zietman AL, Edelstein RA, Coen JJ, Babayan
RK and Krane RJ: Radical prostatectomy for adenocarcinoma of the
prostate: The influence of preoperative and pathologic findings on
biochemical disease-free outcome. Urology. 43:828–833. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Namiki K and Rosser CJ: Neoadjuvant
therapy and prostate cancer: What a urologist should know. Curr
Opin Urol. 17:188–193. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herman JR, Adler HL, Aguilar-Cordova E,
Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC and
Scardino PT: In situ gene therapy for adenocarcinoma of the
prostate: A phase I clinical trial. Hum Gene Ther. 10:1239–1249.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shalev M, Kadmon D, Teh BS, Butler EB,
Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT
and Miles BJ: Suicide gene therapy toxicity after multiple and
repeat injections in patients with localized prostate cancer. J
Urol. 163:1747–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miles BJ, Shalev M, Aguilar-Cordova E, et
al: Prostate-specific antigen response and systemic T cell
activation after in situ gene therapy in prostate cancer patients
failing radiotherapy. Hum Gene Ther. 12:1955–1967. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thompson TC: In situ gene therapy for
prostate cancer. Oncol Res. 11:1–8. 1999.PubMed/NCBI
|
|
10
|
Freeman SM, Abboud CN, Whartenby KA,
Packman CH, Koeplin DS, Moolten FL and Abraham GN: The ‘bystander
effect’: Tumor regression when a fraction of the tumor mass is
genetically modified. Cancer Res. 53:5274–5283. 1993.PubMed/NCBI
|
|
11
|
Barba D, Hardin J, Sadelain M and Gage FH:
Development of anti-tumor immunity following thymidine
kinase-mediated killing of experimental brain tumors. Proc Natl
Acad Sci USA. 91:4348–4352. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gagandeep S, Brew R, Green B, Christmas
SE, Klatzmann D, Poston GJ and Kinsella AR: Prodrug-activated gene
therapy: Involvement of an immunological component in the
‘bystander effect’. Cancer Gene Ther. 3:83–88. 1996.PubMed/NCBI
|
|
13
|
Ayala G, Wheeler TM, Shalev M, Thompson
TC, Miles B, Aguilar-Cordova E, Chakraborty S and Kadmon D:
Cytopathic effect of in situ gene therapy in prostate cancer. Hum
Pathol. 31:866–870. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Satoh T, Teh BS, Timme TL, et al: Enhanced
systemic T-cell activation after in situ gene therapy with
radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol
Phys. 59:562–571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hall SJ, Mutchnik SE, Chen SH, Woo SL and
Thompson TC: Adenovirus-mediated herpes simplex virus thymidine
kinase gene and ganciclovir therapy leads to systemic activity
against spontaneous and induced metastasis in an orthotopic mouse
model of prostate cancer. Int J Cancer. 70:183–187. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hall SJ, Sanford MA, Atkinson G and Chen
SH: Induction of potent antitumor natural killer cell activity by
herpes simplex virus-thymidine kinase and ganciclovir therapy in an
orthotopic mouse model of prostate cancer. Cancer Res.
58:3221–3225. 1998.PubMed/NCBI
|
|
17
|
Hassan W, Sanford MA, Woo SL, Chen SH and
Hall SJ: Prospects for herpes-simplex-virus thymidine-kinase and
cytokine gene transduction as immunomodulatory gene therapy for
prostate cancer. World J Urol. 18:130–135. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Loimas S, Toppinen MR, Visakorpi T, Jänne
J and Wahlfors J: Human prostate carcinoma cells as targets for
herpes simplex virus thymidine kinase-mediated suicide gene
therapy. Cancer Gene Ther. 8:137–144. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vile RG, Castleden S, Marshall J,
Camplejohn R, Upton C and Chong H: Generation of an anti-tumour
immune response in a non-immunogenic tumour: HSVtk killing in vivo
stimulates a mononuclear cell infiltrate and a Th1-like profile of
intratumoural cytokine expression. Int J Cancer. 71:267–274. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kianmanesh AR, Perrin H, Panis Y, Fabre M,
Nagy HJ, Houssin D and Klatzmann D: A ‘distant’ bystander effect of
suicide gene therapy: Regression of nontransduced tumors together
with a distant transduced tumor. Hum Gene Ther. 8:1807–1814. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Whartenby KA, Abboud CN, Marrogi AJ,
Ramesh R and Freeman SM: The biology of cancer gene therapy. Lab
Invest. 72:131–145. 1995.PubMed/NCBI
|
|
22
|
Satoh T, Kubo M, Tabata K, et al: Systemic
T-cell activation following neoadjuvant in situ gene therapy in
high-risk prostate cancer patients. J Urol. 187:e3232012.
View Article : Google Scholar
|
|
23
|
Ayala G, Satoh T, Li R, Shalev M, Gdor Y,
Aguilarcordova E, Frolov A, Wheeler T, Miles B and Rauen K:
Biological response determinants in HSV-tk + ganciclovir gene
therapy for prostate cancer. Mol Ther. 13:716–728. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van der Linden RR, Haagmans BL,
Mongiat-Artus P, van Doornum GJ, Kraaij R, Kadmon D,
Aguilar-Cordova E, Osterhaus AD, van der Kwast TH and Bangma CH:
Virus specific immune responses after human neoadjuvant
adenovirus-mediated suicide gene therapy for prostate cancer. Eur
Urol. 48:153–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
